European Medicines Agency accepts TiGenix Paediatric

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
European Medicines Agency accepts TiGenix Paediatric Investigation Plan for Cx601

LEUVEN, Belgium, Sept. 8, 2014 (GLOBE NEWSWIRE) -- TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today that the Paediatric Committee of the European Medicines Agency (EMA) has issued a positive opinion on the Company's Paediatric Investigation Plan (PIP) for Cx601, a locally injected stem cell product in Phase III of clinical development for the treatment of complex perianal fistulas in patients with Crohn's disease.

An accepted PIP is a requirement for the filing for marketing authorisation of a new medicinal product with the EMA. It describes how a company intends to evaluate the use of the new product in children. On completion of the PIP, the company is awarded an additional six months' patent exclusivity for the product. Cx601 received Orphan Drug designation from the EMA in 2009 giving it ten years' market exclusivity from the date of marketing authorisation.

The PIP for Cx601 consists of one open-label, multi-centre, non-comparative trial to evaluate the activity of Cx601 for the treatment of complex anal fistulas in at least 20 Crohn's disease patients aged from 4-17 years. The study will assess efficacy and safety. The primary endpoint will be remission of perianal fistulising Crohn's disease at week 24, defined as closure of all external openings that were draining at the start of the study. The study will have a follow-up period of one year.

"We are pleased with the EMA's positive opinion on our PIP for Cx601 which allows us to keep moving towards our filing for marketing authorisation for Cx601 in the first half of 2016," said Maria Pascual, VP Regulatory Affairs and Corporate Quality at TiGenix. "Building on the strength of the adult development program and the body of data to be accumulated at the post-marketing phase, a very focused trial has been agreed with the Agency. The study will not begin before 2020, three years after our planned launch of Cx601 in 2017."

For more information:

Richard Simpson
Senior Consultant, Comfi sprl
T: +32 494 578 278
richard@comfi.be

About Cx601

Cx601 is a suspension of allogeneic expanded adipose-derived stem cells (eASCs) delivered locally through intra-lesional injection. Cx601 is being developed for the treatment of perianal fistulas in Crohn's disease patients. Crohn's disease is a chronic inflammatory disease of the intestine and patients can suffer from complex perianal fistulas for which there is currently no effective treatment. In 2009, the European Commission granted Cx601 orphan designation for the treatment of anal fistulas, recognising the debilitating nature of the disease and the lack of treatment options. In a Phase II clinical trial, Cx601 showed efficacy at 24 weeks in 56% of treated fistula tracts, which is more than two times higher than the current standard of care (TNF inhibitors). Efficacy was measured as the complete closure and re-epithelisation of the fistula being treated with an absence of drainage. Additionally, 69.2% of patients demonstrated a reduction in the number of initially draining tracts. The trial also confirmed the safety of the use of allogeneic stem cells for the treatment of perianal fistula. Based on these results, TiGenix sought scientific advice from the European Medicines Agency (EMA) on the future development path of Cx601. TiGenix then initiated a randomised, double-blind, placebo-controlled Phase III trial in Europe and Israel (278 recruited patients, 8 countries, 52 centres) designed to comply with the requirements laid down by the EMA. This pivotal study is intended to enable filing for marketing authorisation in Europe and to serve as a key supportive study in filing for approval in other territories, including the US. The study's primary end-point is remission of the fistulous disease, defined as 100% healing of the tracts. The trial has a first complete analysis of results at 24 weeks, with a follow-up analysis to be performed at 52 weeks post-treatment. Evaluation of healing includes both clinical assessment and MRI confirmation (lack of abscesses larger than 2 cm²). The Phase III clinical trial began patient recruitment in mid-2012, and recruitment of the whole sample of patients is expected to be completed in the course of 2014. The first clinical report is expected to be available in the third quarter of 2015. With positive results, TiGenix intends to submit a request for marketing authorisation with the EMA early in 2016, so that a decision by the European Commission could be expected towards the end of 2016. TiGenix is preparing to develop Cx601 for the US market. The company intends to appoint a contract manufacturing organisation (CMO) in the US with whom it will then begin the technology transfer to enable production of Cx601 in the US; and the company will file for a Special Protocol Assessment (SPA) from the FDA to ensure that the design of a new Phase III study to be done in the US is aligned with the Agency's requirements for future approval of Cx601.

About TiGenix

TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, or donor-derived, expanded adipose-derived stem cells, known as eASCs, in inflammatory and autoimmune diseases. Two products from this technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn's disease patients. Cx611 is in Phase IIb for early rheumatoid arthritis, and in Phase Ib for severe sepsis. TiGenix also developed ChondroCelect, an autologous cell therapy product for cartilage repair of the knee, which was the first Advanced Therapy Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA). From June 2014, the marketing and distribution rights of ChondroCelect have been exclusively licensed to Sobi for the European Union (except for Finland, where it is distributed by the Finnish Red Cross Blood Service), Norway, Russia, Switzerland and Turkey, and the countries of the Middle East and North Africa. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain). For more information, please visit  www.tigenix.com

Forward-looking information

This document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.

Press release (PDF) http://hugin.info/137616/R/1854253/648435.pdf

HUG#1854253

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Home Energy Tips: Embrace the Electrical Panel Shift

Updated Category News Views 13

Why Electrical Panels Matter More Than Ever Back in the day, electrical panels weren't exactly the star of the homeowner show. But times have changed, and those previously mundane boxes of switches and wires now demand a spotlight. Shifts in modern lifestyles have catapulted electrical systems into the spotlight, making upgrades a pressing conversation topic for savvy...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 75

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 147

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 106

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 170

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Dr. Obeng Joins WellcomeMD with Special Offer for Patients

Updated Category News Views 23

New Beginnings in Concierge Medicine In late October, WellcomeMD opened its doors to Dr. Paa-Kofi Obeng—an arrival greeted with considerable anticipation in Richmond's medical scene. This isn't just any run-of-the-mill staff addition; Dr. Obeng brings with him over a decade of experience from places like the Veterans Administration Medical Center. He's armed with a...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 111

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
The Melt Grabs Top Spot in Burger Ratings War

Updated Category News Views 40

Burger Battle: The Melt Claims Victory When you're in the cutthroat world of fast-casual dining, grabbing the top spot on any list is no small potatoes. The Melt did just that, snatching the title of America’s Highest-Rated Burger Spot. Based on an in-depth analysis of Google and Yelp reviews, folks have spoken, loud and clear, over the past two years. It's a world...

Continue Reading
Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 87

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 52

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating Consumer Trust: The Most Trusted Brands of 2026

Updated Category News Views 270

Consumer Trust at the Core of Shopping Decisions In an ever-competitive marketplace, consumers face an overwhelming array of choices, making decisions increasingly challenging. Fortunately, trust acts as a guiding beacon for shoppers, allowing them to confidently narrow down their options when making purchases. According to the BrandSpark American Trust Study, a...

Continue Reading
Saudi AI Hackathon 2025: Empowering Student Innovators

Updated Category News Views 215

Saudi AI & Edge Computing Hackathon 2025 Fosters Innovation In a remarkable showcase of talent and creativity, the Saudi AI & Edge Computing Hackathon 2025 took center stage, emphasizing the synergy between academia and the tech industry. Hosted by Prince Sultan University and backed by MemryX, this hackathon highlighted the exceptional capabilities of students from...

Continue Reading
Meta Implements AI Hiring Freeze Amid Talent Competition

Updated Category News Views 312

Meta Platforms Inc. Takes a Step Back in AI Hiring Meta Platforms Inc. (NASDAQ: META) has recently instituted a hiring freeze in its artificial intelligence division. This decision follows months of aggressive recruitment, during which the company significantly boosted its talent pool with substantial compensation offers. The freeze is aimed at regulating the hiring...

Continue Reading
Lady Gaga's Heartfelt Cover of 'Won't You Be My Neighbor?' in Super Bowl Teaser

Updated Category News Views 148

Lady Gaga Celebrates Community with New Cover In a touching tribute to the spirit of neighborliness, Lady Gaga has graced the world with her cover of "Won't You Be My Neighbor?". This initiative is part of a larger campaign that dives deep into themes of home, community, and belonging. Behind the Scenes of the Teaser Fans can catch exclusive behind-the-scenes footage...

Continue Reading
Palo Alto Networks Plummets: Guidance Cut or Market Misread?

Updated Category News Views 245

Palo Alto Networks took a nosedive, with shares down over 7% premarket, sitting at $151.69—a shocker for traders who were banking on bullish momentum. The cybersecurity giant's fiscal second-quarter report dropped Tuesday, revealing a mixed bag that left investors scrambling to recalibrate expectations. While the top line reported $2.59 billion in revenue—just edging...

Continue Reading